CRISPR/Cas9 for Environmental Sustainability and Ecosystem Protection
32 13
DOI:
https://doi.org/10.5281/zenodo.18640804Keywords:
CRISPR-Cas9, gene editing, environmental biotechnology, ecology, biodiversity conservation, sustainable developmentAbstract
The development of CRISPR/Cas9 genome editing technology has revolutionized modern biotechnology, offering powerful tools not only for medicine and agriculture but also for addressing critical environmental challenges. This review examines recent advances in CRISPR/Cas9 technology with a particular focus on its applications in ecology and environmental sustainability. The use of CRISPR-based approaches enables the conservation of biodiversity through genetic rescue of endangered species and the control of invasive organisms that disrupt ecosystem balance. In addition, CRISPR/Cas9 has shown significant potential in environmental bioremediation by genetically enhancing microorganisms capable of degrading pollutants, including heavy metals, pesticides, and plastic waste. In agricultural ecosystems, genome editing contributes to the development of climate-resilient crops that reduce reliance on chemical inputs, thereby minimizing ecological damage to soil and water systems. The review also discusses ethical, ecological, and biosafety considerations associated with releasing gene-edited organisms into natural environments, emphasizing the need for robust regulatory frameworks. Overall, CRISPR/Cas9 represents a transformative technology for promoting ecosystem stability, environmental protection, and sustainable development under changing global conditions.
References
Adhikari, P., & Poudel, M. (2020). CRISPR-Cas9 in agriculture: Approaches, applications, future perspectives, and associated challenges. Malaysian Journal of Halal Research, 3(1), 6–12. https://doi.org/10.2478/mjhr-2020-0002
Barrett, C. B. (2020). Overcoming global food security challenges through science and solidarity. American Journal of Agricultural Economics, 103(2), 422–447. https://doi.org/10.1111/ajae.12160
Bouzroud, S., Gasparini, K., Hu, G., Ayadi, M., Bouzid, R. G., & Pirrello, J. (2020). Down-regulation and loss of auxin response factor 4 function using CRISPR/Cas9 alters plant growth, stomatal function, and improves tomato tolerance to salinity and osmotic stress. Genes, 11(3), 272. https://doi.org/10.3390/genes11030272
Chen, Z. J., Zhai, X. Y., Liu, J., Zhang, N., & Yang, H. (2023). Detoxification and catabolism of mesotrione and fomesafen facilitated by a Phase II reaction acetyltransferase in rice. Journal of Advanced Research, 51, 1–11. https://doi.org/10.1016/j.jare.2022.12.002
Cui, Y., Jiang, N., Xu, Z., Huang, Y., Wang, Y., Hu, J., Zhu, X., & He, X. (2020). Heterotrimeric G proteins are involved in the regulation of multiple agronomic traits and stress tolerance in rice. BMC Plant Biology, 20, 90. https://doi.org/10.1186/s12870-020-2289-6
Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013). Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Scientific Reports, 3, Article 2510. https://doi.org/10.1038/srep02510
Fontana, M., Solomon, S. D., Kachadourian, J., Walsh, L., Rocha, R., Lebwohl, D., Smith, D., Taubel, J., Gane, E. J., Pilebro, B., Adams, D., Razvi, Y., Olbertz, J., Haagensen, A., Zhu, P., Xu, Y., Leung, A., Sonderfan, A., Gutstein, D. E., & Gillmore, J. D. (2024). CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy. The New England Journal of Medicine, 391(23), 2231–2241. https://doi.org/10.1056/NEJMoa2412309
Iyer, S. P., Sica, R. A., Ho, P. J., Prica, A., Zain, J., Foss, F. M., Hu, B., Beitinjaneh, A., Weng, W.-K., Kim, Y. H., Khodadoust, M. S., Huen, A. O., Williams, L. M., Ma, A., Huang, E., Ganpule, A., Nagar, S. D., Sripakdeevong, P., Cullingford, E. L., & Horwitz, S. M. (2025). Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): A single-arm, open-label, phase 1, dose-escalation study. The Lancet Oncology, 26(1), 110–122. https://doi.org/10.1016/S1470-2045(24)00508-4
Kolanu, N. D. (2024). CRISPR–Cas9 gene editing: Curing genetic diseases by inherited epigenetic modifications. Global Medical Genetics, 11(1), 113–122. https://doi.org/10.1055/s-0044-1785234
Kuprešanin, A., Jarić, S., Novaković, Z., Đurđević, P., Radovanović, M., & Nikolić, M. (2025). Future perspectives of GMO detection in agriculture: Strategies for electrochemical nucleic acid detection. Microchimica Acta, 192, 457. https://doi.org/10.1007/s00604-025-07267-x
Li, M., Li, X., Zhou, Z., Wu, P., Fang, M., Pan, X., Lin, Q., Luo, W., Wu, G., & Li, H. (2016). Reassessment of the four yield-related genes Gn1a, DEP1, GS3, and IPA1 in rice using a CRISPR/Cas9 system. Frontiers in Plant Science, 7, 377. https://doi.org/10.3389/fpls.2016.00377
Lou, E., Choudhry, M. S., Starr, T. K., Folsom, T. D., Bell, J., Rathmann, B., DeFeo, A. P., Kim, J., Slipek, N., Jin, Z., Sumstad, D., Klebanoff, C. A., Ladner, K., Sarkari, A., McIvor, R. S., Murray, T. A., Miller, J. S., Rao, M., Jensen, E., & Moriarity, B. S. (2025). Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: A first-in-human, single-centre, phase 1 trial. The Lancet Oncology, 26(5), 559–570. https://doi.org/10.1016/S1470-2045(25)00083-X
Muha-Ud-Din, G., Ali, F., Hameed, A., Naqvi, S. A. H., Nizamani, M. M., Jabran, M., Sarfraz, S., & Yong, W. (2024). CRISPR/Cas9-based genome editing: A revolutionary approach for crop improvement and global food security. Physiological and Molecular Plant Pathology, 129, 102191. https://doi.org/10.1016/j.pmpp.2023.102191
Pal, S., Krishna, R., Dedhia, L., Panwar, H. S., Karkute, S. G., Rai, N., Kumar, R., Pandey, S., & Singh, A. K. (2025). CRISPR-mediated gene editing for economically important traits in horticultural crops: Progress and prospects. Transgenic Research, 34(1), Article 26. https://doi.org/10.1007/s11248-025-00444-x
Sharma, A., Boelens, J.-J., Cancio, M., Hankins, J. S., Bhad, P., Azizy, M., Lewandowski, A., Zhao, X., Chitnis, S., Peddinti, R., Zheng, Y., Kapoor, N., Ciceri, F., Maclachlan, T., Yang, Y., Liu, Y., Yuan, J., Naumann, U., Yu, V. W. C., Stevenson, S. C., De Vita, S., & LaBelle, J. L. (2023). CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease. The New England Journal of Medicine, 389(9), 820–832. https://doi.org/10.1056/NEJMoa2215643
Tester, M., & Langridge, P. (2011). Feeding the extra billions: Strategies to improve crops and enhance future food security. Plant Biotechnology Reports, 5(2), 107–120. https://doi.org/10.1007/s11816-011-0189-3
Wang, X., Wu, X., Tan, B., Zhu, L., Zhang, Y., Lin, L., Xiao, Y., Sun, A., Wan, X., Liu, S., Liu, Y., Ta, N., Zhang, H., Song, J., Li, T., Zhou, L., Yin, J., Ye, L., Lu, H., & Xu, H. (2024). Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell, 187(18), 4890–4904.e9. https://doi.org/10.1016/j.cell.2024.06.027
Wei, A., Yin, D., Zhai, Z., Ling, S., Le, H., Tian, L., Xu, J., Paludan, S. R., Cai, Y., & Hong, J. (2023). In vivo CRISPR gene editing in patients with herpetic stromal keratitis. Molecular Therapy, 31(11), 3163–3175. https://doi.org/10.1016/j.ymthe.2023.08.021
Wei, W., Chen, Z.-N., & Wang, K. (2023). CRISPR/Cas9: A powerful strategy to improve CAR-T cell persistence. International Journal of Molecular Sciences, 24(15), 12317. https://doi.org/10.3390/ijms241512317
